KRAS / RAS targeting: from platform to Phase 3
daraxonrasib ± GnP · mono ORR 47%; +GnP ORR 55%, DCR 90%
Presidential session #2 #AACR26
Dr. Mischel
@StanfordMed
Advancing cancer science to save lives
@carlhjune
@Penn
CAR-T applications solid tumors
Promising delivered locally #GBM
How to tune with #CAE for #PDAC
Promising #CART #solidtumors
@AACR
@OncoAlert
Heat 14 · 8 likes · 1 reply · 5 reposts
Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque
Read the abstract →Eileen M. O'Reilly, Brian Wolpin, Shubham Pant, Joel Randolph Hecht, Jennifer Valerin, Dae Won Kim, Nilofer Azad, Kyaw Aung, Lin Tao, Sumit Kar, Hina Patel, Rashmi Vora, Aparna Hegde, Alexander Spira, Alexander Starodub, Benjamin Herzberg, Ignacio Garrido-Laguna
Read the abstract →Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal
Read the abstract →Source: Oriol Mirallas MD · x.com